Sinopharm Group (1099.HK) - Performance Pressure May Continue Until 2024H1
Weaker-than-expected performance in 23Q1-Q3 dragged down Sinopharm’s full-year performance growth. Single-digit growth seems inevitable. The...
999 Views
HK Connect SOUTHBOUND Flows (To 15Dec23); CNOOC/Telecom/Mobile All Now To The Buy Side, Tencent NOT
SOUTHBOUND HK Connect Flows were lower than previous weeks in stock-picking but flows on ETFs were significant. NET flows were HK$9.9bn to the sell...
652 Views
YSB (9885.HK) - Being Included in ETF Offers a Great Escape Opportunity
YSB's being added to KWEB offers a golden opportunity for cornerstone investors to cash out. If these people choose to escape, it's time to...
525 Views
Pre-IPO Beijing Yuanxin Technology Group - Some Points Worth the Attention
Yuanxin has weak profitability. It's questionable whether investors can achieve expected returns on this company.We think Yuanxin may eventually be...
629 Views
Sinopharm Group (1099.HK) 23H1 - Strong Growth Would Continue, but Profit Margin Is Under Pressure
Sinopharm’s performance growth in 23H1 was satisfactory, which is expected to maintain in 23H2, leading to optimistic full year performance....
717 Views